Somatic Mutation in Immunoglobulin Gene Variable Region in Patients with Chronic Lymphocytic Leukemia and Prognostic Impact
Abstract
Chronic lymphocyte leukemia (CLL) is the most common leukemia in elderly individuals that is accompanied by the presence of CD5/CD19/CD20/CD23 positive, FMC7 negative and reduced levels of surface membrane Immunoglobuline (IgM & IgD), CD79b on B lymphocytes in the blood, bone marrow and lymph nodes. Remarkably, based on the mutational IgVH status, B-CLL cases can be subdivided into two prognostic groups: the first one with presence mutation (≥ 2%) in VH gene and second one with absence mutation (≤ 2%) in VH gene that is the mutation of IgVH status, affected on progression and overall survival of CLL patients. Correspondingly, also the expression level of several markers is correlated with the mutation of IgVH status and prognosis of CLL disease. In this review we focused on relation between mutation IgVH status and CLL prognosis and overall survival and also some cellular markers which may affect CLL clinical status.Riches JC, Ramsay AG, Gribben JG. Immune Reconstitu-tion in Chronic Lymphocytic Leukemia. Curr Hematol Ma- lig Rep. 2012;7(1):13-20.
Kiaii S, Kokhaei P, Mozaffari F, Rossmann E, Pak F, Moshfegh A, et al. T cells from indolent CLL patients pre- vent apoptosis of leukemic B cells in vitro and have altered gene expression profile. Cancer Immunol Immunother.2013;62(1):51-63.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
Hojjat-Farsangi M, Jeddi-Tehrani M, Razavi SM, Sharifi-an RA, Mellstedt H, Shokri F, et al. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocyt- ic leukemia. Cancer Sci. 2009;100(12):2346-53.
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leu- kemia. Blood. 1975;46(2):219-34.
Magnac C, Porcher R, Davi F, Nataf J, Payelle-Brogard B, Tang RP, et al. Predictive value of serum thymidine ki- nase level for Ig-V mutational status in B-CLL. Leukemia.2003;17(1):133-7.
Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103(4):1202-10.
Khan AS, Hojjat-Farsangi M, Daneshmanesh AH, Hans- son L, Kokhaei P, Osterborg A, et al. Dishevelled proteins are significantly upregulated in chronic lymphocytic leukae- mia. Tumour Biol. 2016;37(9):11947-57.
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leu- kemia. Blood. 1999;94(6):1840-7.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Steven- son FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood.1999;94(6):1848-54.
Rossi D, Gaidano G. Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leu- kemia. Haematologica. 2010;95(12):1992-5.
Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-15.
Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003;21(1):841-94.
Stevenson FK, Caligaris-Cappio F. Chronic lymphocyt- ic leukemia: revelations from the B-cell receptor. Blood. 2004;103(12):4389-95.
Schebesta M, Heavey B, Busslinger M. Transcription- al control of B-cell development. Curr Opin Immunol. 2002;14(2):216-23.
Chiorazzi N, Ferrarini M. Cellular origin (s) of chronic lymphocytic leukemia: cautionary notes and additional con- siderations and possibilities. Blood. 2011;117(6):1781-91.
Bahler DW, Pindzola JA, Swerdlow SH. Splenic margin- al zone lymphomas appear to originate from different B cell types. Am J Pathol. 2002;161(1):81-8.
Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the nov- el phenotype CD20+ CD27+ CD43+ CD70−. J Exp Med.2011;208(1):67-80.
Schroeder HW, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15(6):288-94.
Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Al- len SL, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102(8):1515.
Dighiero G. CLL biology and prognosis. Hematology Am. Soc. Hematol. Educ. Program. 2005;2005(1):278-84.
Hwang KK, Trama AM, Kozink DM, Chen X, Wiehe K, Cooper AJ, et al. IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria. PLoS ONE. 2014;9(3):e90725.
Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, Hultdin M, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99(6):2262-4.
Bilous N, Abramenko I, Kryachok I, Bazyka D, Chumak A, Bebeshko V. Significance of VH genes mutation status for prognosis of CLL patients. Exp Oncol. 2005;27(4):325-9.
Ghiotto F, Fais F, Albesiano E, Sison C, Valetto A, Gaidano G, et al. Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia. Mol Med. 2006;12(11-12):300-8.
Tobin G, Thunberg U, Johnson A, Eriksson I, Söderberg O, Karlsson K, et al. Chronic lymphocytic leukemias utiliz- ing the VH3-21 gene display highly restricted Vλ2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003;101(12):4952-7.
Tobin G, Thunberg U, Karlsson K, Murray F, Laurell A, Willander K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen se- lection in the development of chronic lymphocytic leukemia. Blood. 2004;104(9):2879-85.
Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J, et al. Multiple distinct sets of stereotyped anti- gen receptors indicate a role for antigen in promoting chron- ic lymphocytic leukemia. J Exp Med. 2004;200(4):519-25.
Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109(1):259-70.
Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, et al. Stereotyped patterns of so- matic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111(3):1524-33.
Rendeiro AF, Schmidl C, Strefford JC, Walewska R, Davis Z, Farlik M, et al. Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. Nat Commun. 2016;7:11938
Seifert M, Sellmann L, Bloehdorn J, Wein F, Stil- genbauer S, Dürig J, et al. Cellular origin and pathophys- iology of chronic lymphocytic leukemia. J Exp Med. 2012;209(12):2183-98.
Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev. 2008;22(4):211-9.
Gaidano G. Molecular pathogenesis of chronic lympho- cytic leukemia. J Clin Invest. 2012;122(10):3432-8.
Xu W, Shen QD, Yu H, Qiao C, Wu YJ, Liu Q, et al. [Li- poprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prog- nostic factors]. Zhonghua Xue Ye Xue Za Zhi. 2009;30(1):8-2.
Meuleman N, Stamatopoulos B, Dejeneffe M, El Housni H, Lagneaux L, Bron D. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and un- treated stage A chronic lymphocytic leukemia patients. Leu- kemia. 2008;22(10):1882-90.
Kern W, Dicker F, Schnittger S, Haferlach C, Hafer- lach T. Correlation of flow cytometrically determined ex- pression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. Cytometry B Clin Cytom.2009;76(6):385-93.
el-Sharnouby JA, el-Shakankiri AA, Hendy OM, Ahmed LM, Taha AM. Significance of zeta-associated protein (ZAP-
and CD38 expression in chronic lymphocytic leukemia. Egypt J Immunol. 2006;13(2):69-84.
Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated im- munoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101(12):4944-51.
Dianzani U, Funaro A, DiFranco D, Garbarino G, Bragardo M, Redoglia V, et al. Interaction between endothe- lium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule. J Immuno. 1994;153(3):952-9.
Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011;118(13):3470-8.
Manocha S, Matrai Z, Osthoff M, Carter A, Pettitt AR. Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44(5):797-800.
Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, et al. V(H) mutation status, CD38 expression lev- el, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4):1410-6.
Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, et al. Specific expression of ac- tivation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem. 1999;274(26):18470-6.
Oppezzo P, Vuillier F, Vasconcelos Y, Dumas G, Magnac C, Payelle-Brogard B, et al. Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. Blood. 2003;101(10):4029-32.
Heintel D, Kroemer E, Kienle D, Schwarzinger I, Gleiss A, Schwarzmeier J, et al. High expression of activation-in- duced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia. 2004;18(4):756-62.
Iida S, Rao PH, Butler M, Corradini P, Boccadoro M,Klein B, et al. Deregulation of MUM1/IRF4 by chro- mosomal translocation in multiple myeloma. Nat Genet. 1997;17(2):226-30.
Marecki S, Fenton MJ. The role of IRF-4 in transcription- al regulation. J Interferon Cytokine Res. 2002;22(1):121-33.
Pernis AB. The role of IRF-4 in B and T cell activation and differentiation. J Interferon Cytokine Res. 2002;22(1):111-20.
Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L, et al. IRF4 mutations in chronic lym- phocytic leukemia. Blood. 2011;118(10):2827-9.
Maloum K, Davi F, Merle-Béral H, Pritsch O, Magnac C, Vuillier F, et al. Expression of unmutated V H genes is a det- rimental prognostic factor in chronic lymphocytic leukemia. Blood. 2000;96(1):377-9.
Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic fac- tors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prog- nostic factors. Blood. 2002;100(4):1177-84.
| Files | ||
| Issue | Vol 8 No 4 (2016) | |
| Section | Reviews | |
| Keywords | ||
| CLL mutation IgVH status prognosis factor overall survival | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
